Setmelanotide Cuts BMI 16.5% in Hypothalamic Obesity Trial: Christian Roth, MD

Setmelanotide produced a mean body mass index (BMI) reduction of 16.5% in patients with acquired hypothalamic obesity, compared with a 3.3% increase among those receiving placebo, according to trial data discussed by principal investigator Christian Roth, MD, a pediatric endocrinologist at Seattle Children's.

Mechanism Targets Hypothalamic Injury

Acquired hypothalamic obesity, often caused by brain tumors or their treatment, has historically resisted standard obesity therapies, including glucagon-like peptide-1 receptor agonists and bariatric surgery. Roth explained that hypothalamic injury can damage agouti-related peptide and proopiomelanocortin neurons responsible for energy homeostasis, leading to a deficiency in melanocyte-stimulating hormone (MSH) signaling, hyperphagia, and reduced energy expenditure. Setmelanotide targets the melanocortin-4 receptor pathway directly, addressing this underlying mechanism.

"Once the MSH deficiency is corrected, then we have normal regulation of energy homeostasis, and we can use other drugs in combination," Roth said.

Beyond weight loss, the trial documented significant reductions in hunger scores. Roth said hyperphagia drives much of the burden on patients and families, who often must lock refrigerators and food cabinets. With treatment, he said, "food is not a major topic anymore," allowing patients to return to normal social functioning.

Adverse Events Require Careful Monitoring

Serious adverse events, including those tied to adrenal insufficiency and vasopressin deficiency management, occurred more frequently in the treatment group. Roth emphasized that setmelanotide does not cause adrenal insufficiency but can complicate its management by altering appetite and fluid intake, requiring clinicians to monitor closely for adrenal crisis symptoms and adjust desmopressin dosing accordingly.

Setmelanotide received FDA approval for acquired hypothalamic obesity in March 2026, and Roth said an ongoing extension study will assess long-term durability and safety. Patient testimonials shared by Roth underscored the treatment's impact: 1 adult participant reported losing 85 pounds, while an adolescent described being able to "talk to people about real life" instead of constantly thinking about food.